Ibrutinib in chronic lymphocytic leukaemia: Alone or in combination?

The Lancet Oncology

Volumn 17, Issue 2, 2016, Pages 129-131

  Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; IBRUTINIB; IDELALISIB; PLACEBO; RITUXIMAB; ANTINEOPLASTIC AGENT;

CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CHEMOIMMUNOTHERAPY; CHEMOTHERAPY; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; GOLD STANDARD; HIGH RISK PATIENT; HUMAN; IMMUNOTHERAPY; LYMPHOCYTOSIS; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NOTE; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; BLEEDING; CHEMICALLY INDUCED; FEMALE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HEMORRHAGE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE;

EID: 84959335509     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00519-7     Document Type: Note

References (10)

1. Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015, 26(suppl 5):v78-v84.
2. Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multi-center phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011, 29:3559-3566.
3. Byrd JC, Furman RR, Coutre SE, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013, 369:32-42.
4. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014, 371:213-223.
5. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014, 370:997-1007.
6. Brown JR, Barrientos JC, Barr PM, et al. The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood 2015, 125:2915-2922.
7. Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma: a randomised, double-blind, phase 3 study. Lancet Oncol 2015, for the HELIOS investigators, published online Dec 4. http://dx.doi.org/10.1016/S1470-2045(15)00465-9.
8. Woyach JA, Smucker K, Smith LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood 2014, 123:1810-1817.
9. Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 2014, 15:1090-1099.
10. Skarzynski M, Niemann CU, Lee YS, et al. Interactions between ibrutinib and anti-CD20 antibodies: competing effects on the outcome of combination therapy. Clin Cancer Res 2015, published online Aug 17. 10.1158/1078-0432.CCR-15-1304.